SCHEMBL3801237

SCHEMBL3801237

O=C(O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)C[C@H]1COc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 20/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140490 1.00 FFAR4 (0.52) FFAR4
SCHEMBL3796231 1.00 FFAR4 (0.52) FFAR4
SCHEMBL1705632 1.00 FFAR4 (0.52) FFAR4
SCHEMBL1140672 0.86 CTSS (0.48) FFAR4
SCHEMBL27851271 0.86 CTSS (0.48) FFAR4
SCHEMBL3794151 0.84 CTSS (0.40) FFAR4
SCHEMBL3802037 0.84 CTSS (0.40) FFAR4
SCHEMBL1707007 0.84 CTSS (0.44) FFAR4
SCHEMBL1139433 0.84 CTSS (0.44) FFAR4
SCHEMBL3803577 0.84 CTSS (0.44) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP claimed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US claimed
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP disclosed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES TBXA2R, ADORA1, CNR1 FFAR4 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.